Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
… all patients. There were no adverse events associated with the anifrolumab treatment.Abstract PO:11:288 Table 1Baseline characteristics of…
…o investigate DORIS remission attainment following subcutaneous anifrolumab initiation among patients with SLE who are naïve to conventiona…
…loading dose. In addition to corticosteroids and antimalarials, ANI was administered in many cases concomitantly with other immunom…
… including fatigue, musculoskeletal pain and morning stiffness. Dapirolizumab pegol (DZP) is a novel CD40L inhibitor with broad modulatory effects …
…endent clinical trials: BEAT-lupus and CALIBRATE both comparing belimumab after rituximab vs. rituximab. We further evaluated its potenti…
…y a significant role in extrarenal DM achievement, particularly cyclophosphamide. These results underscore the importance of addressing SDH and …
… outcomes, from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP is a novel CD40L inhibitor with broad modulatory effe…
…using data from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP, a novel CD40L inhibitor, consists of a polyethylene …
…ory values. The patient was then discharged on a stable dose of ruxolitinib, anakinra and prednisone. This case illustrates the therapeutic…
… confirming IMV. She improved rapidly with oral prednisone, and methotrexate was initiated as a steroid-sparing agent. This case highlights …
…SA (Ro) and anti-sp100 positivity. The patient was treated with doxycycline, high-dose hydroxychloroquine and prednisone, resulting in sign…
…y signals. These preliminary data support further evaluation of ruxolitinib as an adjunctive therapy for severe CIP. ClinicalTrials.gov Ide…